Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference
10. Januar 2025 07:30 ET
|
Royalty Pharma plc
2024 Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting development-stage pipeline with potential for peak royalties of >$1.2 billion;...
Royalty Pharma Announces Transformative Step in Company’s Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program
10. Januar 2025 07:15 ET
|
Royalty Pharma plc
Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLCSignificant annual cash savings of greater than $100 million in 2026 growing to over $175...
Royalty Pharma Announces Dividend Increase
09. Januar 2025 16:15 ET
|
Royalty Pharma plc
NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2025 of $0.22 per Class A...
Royalty Pharma to Present at Upcoming Investor Conferences
27. November 2024 16:15 ET
|
Royalty Pharma plc
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of December: ...
Royalty Pharma Announces Inaugural Prize for Impact in Healthcare
14. November 2024 16:30 ET
|
Royalty Pharma plc
Royalty Pharma inaugural Prize for Impact in Healthcare awarded to Michael Milken, the founder of the Milken Institute, Faster Cures & the Prostate Cancer FoundationThe Prize includes a charitable...
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million
07. November 2024 07:10 ET
|
Royalty Pharma plc
RYTELO™ (imetelstat) is FDA approved for the treatment of low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemiaTransaction increases Royalty Pharma’s synthetic...
Royalty Pharma Reports Third Quarter 2024 Results
06. November 2024 07:15 ET
|
Royalty Pharma plc
Portfolio Receipts growth of 15% to $735 million; Royalty Receipts growth of 15%Net cash provided by operating activities of $704 millionCapital Deployment of approximately $1.2 billion Raising full...
Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo
04. November 2024 16:15 ET
|
Royalty Pharma plc
Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800...
Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024
16. Oktober 2024 16:15 ET
|
Royalty Pharma plc
NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2024 financial results on Wednesday, November 6, 2024 before the...
Royalty Pharma Declares Fourth Quarter 2024 Dividend
11. Oktober 2024 08:15 ET
|
Royalty Pharma plc
NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2024 of $0.21 per Class A...